The company provides IT consulting, staffing, and Global Capability Center (GCC) services, helping international enterprises establish offshore technology hubs in India while offering specialized AI and Salesforce implementation solutions.
The company operates in a highly fragmented IT services and staffing market with no clear mechanism for a moat; low net margins (1.1%) and poor ROE (1.7%) contradict any claims of a competitive advantage or switching costs.
Capital has been deployed toward setting up new headquarters, international subsidiaries in Canada and the US, and an IT leasing business, yet these investments have resulted in a significant decline in EPS and poor returns on equity.
The investment collapsed as the divergence between vanity revenue growth and actual profitability became unsustainable. Management's aggressive expansion into international subsidiaries and IT leasing failed to generate returns, further diluting the already abysmal 1.7% ROE. The business model eventually buckled under the weight of related-party entanglements and regulatory scrutiny over FEMA compliance, while the contested Patna High Court income—which had artificially propped up earnings—was reversed, exposing the core operation as a low-margin staffing firm with no pricing power and negative cash flow.
RichFakir rates S A Tech Software India Ltd's business quality as poor — 19/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, S A Tech Software India Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on S A Tech Software India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of S A Tech Software India Ltd's fair value is about ₹12 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →